N
BDTX icon

Nuveen’s Black Diamond Therapeutics BDTX Stock Holding History

Nuveen’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-135,587
Closed -$3.33M – 3286
2025
Q1 		$3.33M Sell
135,587
-65,948
-33% -$138K ﹤0.01% 2127
2024
Q4 		$431K Buy
201,535
+22,802
+13% +$65.3K ﹤0.01% 3031
2024
Q3 		$777K Buy
178,733
+56,730
+46% +$309K ﹤0.01% 2860
2024
Q2 		$569K Buy
+122,003
New +$655K ﹤0.01% 2943
2022
Q2 		– Sell
-86,043
Closed -$268K – 3260
2022
Q1 		$268K Buy
86,043
+1,996
+2% +$7.29K ﹤0.01% 3141
2021
Q4 		$419K Sell
84,047
-7,830
-9% -$54.7K ﹤0.01% 3114
2021
Q3 		$873K Buy
91,877
+1,230
+1% +$12.1K ﹤0.01% 3035
2021
Q2 		$1.1M Buy
90,647
+27,696
+44% +$548K ﹤0.01% 2972
2021
Q1 		$1.53M Sell
62,951
-441
-0.7% -$11.9K ﹤0.01% 2734
2020
Q4 		$2.03M Sell
63,392
-2,145
-3% -$70.5K ﹤0.01% 2502
2020
Q3 		$1.98M Buy
65,537
+16,426
+33% +$500K ﹤0.01% 2394
2020
Q2 		$2.07M Buy
49,111
+13,047
+36% +$480K ﹤0.01% 2326
2020
Q1 		$900K Buy
+36,064
New +$1.1M ﹤0.01% 2557

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nuveen's BDTX Position: Q2 2025 in Review

Nuveen sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 135,587 shares — an estimated $3.33M sold.

Nuveen first reported a position in BDTX in Q1 2020 and held it in 13 quarters. The position peaked at $3.33M in Q1 2025. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • Nuveen reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 135,587 Black Diamond Therapeutics shares in Q2 2025, an estimated $3.33M.
  • Nuveen first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 13 quarters.
  • Nuveen's Black Diamond Therapeutics position peaked at $3.33M in Q1 2025.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.